Table 1. Meta-analysis of BCL-2 promoter polymorphisms and cancer risk.

	No.ofstudies	PQ	I2	OR	95% CI	PZ	Model
rs2279115	18(6950/7984)
C vs. A		0.000	74.4%	1.16	1.05,1.29	0.004	Random-effects model
CC+ CA vs. AA		0.000	65.3%	1.19	1.01,1.41	0.039	Random-effects model
CC vs. CA+AA		0.000	67.5%	1.23	1.08,1.41	0.002	Random-effects model
CC vs. CA		0.004	53.8%	1.20	1.07,1.35	0.003	Random-effects model
rs1801018	3(1260/1440)
A vs. G		0.034	70.4%	1.48	0.90,2.44	0.119	Random-effects model
AA+AG vs. GG		0.626	0.00%	1.39	0.66,2.93	0.394	Fixed-effects model
AA vs.AG+GG		0.039	69.1%	1.50	0.90,2.52	0.122	Random-effects model
AA vs. AG		0.057	65.0%	1.46	0.89,2.39	0.134	Random-effects model